A way to avoid axillary dissection, with more neoadjuvant therapy treatments, this may help avoid unnecessary axillary dissection.Probably needs more validation with larger studies but is a good start.Also, the first related to radiological findings, so welcome input from our FCS Radiologists.
New criteria for response to therapy in high grade MDS, focuses on pt centered outcomes.
Neoadjuvant immunotherapy is gaining momentum in breast (triple negative) and lung cancer, now showing promise in MSI high tumors.
Confirms what we already know. No real surprises.
In this study, Cetuximab beat Bevacizumab in left sided KRAS wild type colon cancer.
Three trial updates confirm what we already know and practice.
Confirms what we already know. No real surprises.
Confirms what we already know. No real surprises.
Somewhat disappointing as this was a negative study, however it is still an option for patients who are not candidates for mFOLFIRINOX.
Although immunotherapy did not beat chemotherapy but was non inferior and with more favorable safety.